TL;DR
This study reveals that patients hospitalized with COVID-19 and chronic kidney disease (CKD) face significantly higher mortality and readmission rates, even after accounting for other risk factors. The findings highlight a critical vulnerability in CKD patients, emphasizing the need for increased clinical awareness and tailored management strategies for this population.
What Problem Does This Paper Address?
The COVID-19 pandemic has underscored the importance of identifying and understanding risk factors for severe outcomes. Chronic kidney disease (CKD) has been recognized as a significant comorbidity, but the precise impact of varying CKD stages on COVID-19 mortality and readmission rates, especially in a comprehensive, multi-center setting, remained unclear. Previous research often focused on end-stage renal disease (ESRD) or kidney transplant recipients, leaving a gap in understanding the risks associated with earlier stages of CKD. This paper aims to fill that gap by systematically evaluating mortality and readmission rates across the spectrum of CKD stages in hospitalized COVID-19 patients.
Methods
The researchers conducted a multicenter, retrospective observational cohort study using data from the Dutch COVIDPredict cohort. This cohort included patients hospitalized with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection (CORADS score ≥ 4) between March 2020 and July 2021. Patients were categorized into groups based on their pre-admission CKD stage (using CKD-EPI formula and eGFR) or as controls ("no-CKD"). The primary outcome was a composite endpoint of all-cause mortality or readmission within a 12-week follow-up period. Statistical analyses involved comparing baseline characteristics, vital signs, and laboratory values across groups. Logistic regression was employed to adjust for potential confounders such as age, sex, ethnicity, number of comorbidities, and COVID-19 treatment wave.
Datasets
The study utilized data from the Dutch COVIDPredict cohort, which comprises hospitalized patients from eleven hospitals in the Netherlands. This dataset included patients with PCR-confirmed SARS-CoV-2 infection or highly suspected CT scan-based infection (CORADS score ≥ 4) admitted between March 2020 and July 2021.
Key Insights and Ideas
- CKD is a pervasive risk factor across stages: The study strongly suggests that CKD, not just in its advanced stages, significantly elevates the risk of severe COVID-19 outcomes, including mortality and readmission.
- Beyond ESRD: While kidney transplant (KTX) and dialysis patients are known to be at higher risk, this research highlights that even patients with earlier stages of CKD (stages 3a, 3b, and 4) experience a demonstrably increased risk.
- CKD itself is the driver: The authors found that even after adjusting for numerous confounding factors, the increased risk associated with CKD persisted, suggesting that CKD itself, rather than just its associated comorbidities, is a direct contributor to worse COVID-19 outcomes.
- KTX patients face a particularly high risk: The study identified a notably higher mortality and readmission rate in kidney transplant patients, even after full adjustment, underscoring their heightened vulnerability.
Key Results
- A total of 4151 hospitalized COVID-19 patients were included, with 389 (9.4%) having a history of CKD.
- In the unadjusted model, all CKD stages, except stage 5, were associated with significantly higher mortality and readmission rates compared to the "no-CKD" group.
- After adjusting for confounding variables, patients with CKD stages 3a, 3b, and 4, as well as kidney transplant (KTX) patients, showed significantly increased odds ratios for death and readmission, ranging from 1.96 to 8.94 compared to patients without CKD.
- The fully adjusted model showed that KTX patients had the highest odds ratio for the composite endpoint (4.95), indicating a substantial increase in risk.
- While some complications like congestive heart failure and anemia were more frequent in CKD patients, these did not appear to be the primary drivers of the increased mortality and readmission rates.
Limitations and Future Work
The authors acknowledge several limitations:
- eGFR as the sole severity measure: The study relied on eGFR staging for CKD severity and did not incorporate albuminuria, which is another crucial indicator of CKD severity and progression.
- Exclusion of patients: A significant number of CKD patients (247) were excluded due to missing pre-admission creatinine values, potentially affecting the generalizability of findings to this subgroup.
- Primary diagnosis of CKD: The impact of the underlying cause of CKD on COVID-19 outcomes was not studied due to incomplete data.
- Potential for residual confounding: Despite extensive adjustments, the possibility of overestimation or underestimation of results due to unmeasured confounders remains.
Future work could involve incorporating albuminuria data, investigating the impact of specific CKD etiologies, and exploring the effectiveness of tailored interventions for CKD patients with COVID-19. The authors emphasize the need for clinicians to be aware of the increased vulnerability of CKD patients to severe COVID-19 outcomes.
Summary updated